Table III.
FDA-approved biosimilars in oncology.
| Biosimilar | Reference biologic (Active substance) | Manufacturer | FDA approval date |
|---|---|---|---|
| Zarxio | Neypogen (filgrastim-sndz) | Sandoz Inc. | 06/03/2015 |
| Mvasi | Avastin (bevacizumab-awwb) | Amgen, Inc. | 14/09/2017 |
| Ogivri | Herceptin (trastuzumab-dkst) | Mylan | 01/12/2017 |
| Retacrit | Epogen (epoetin alfa-epbx) | Hospira Inc. | 15/05/2018 |
| Fulphila | Neulasta (pegfligrastim-jmdb) | Mylan/Biocon | 04/06/2018 |
| Nivestym | Neupogen (filgrastim-aafi) | Pfizer Inc. | 20/07/2018 |
| Udenyca | Neulasta (pegfligrastim-cbqv) | Coherus Biosciences | 02/11/2018 |
| Truxima | Rituxan (rituximab-abbs) | Celltrion Inc. | 28/11/2018 |
| Herzuma | Herceptin (trastuzumab-pkrb) | Celltrion Inc. | 18/12/2018 |
| Ontruzant | Herceptin (trastuzumab-dttb) | Samsung Bioepis | 18/01/2019 |
| Trazimera | Herceptin (trastuzumab-qyyp) | Pfizer Ind. | 11/03/2019 |
| Kanjinti | Herceptin (trastuzumab-anns) | Amgen Inc. | 13/06/2019 |
| Zirabev | Avastin (bevacizumab-bvzr) | Pfizer Inc. | 28/06/2019 |
| Ruxience | Rituxan (rituximab-pvvr) | Pfizer Inc. | 23/07/2019 |